Covalon Technologies Ltd (TSE:COV)
:COV
Want to see TSE:COV full AI Analyst Report?
COV Stock Chart & Stats
C$1.75
-C$0.04(-1.22%)
At close: 4:00 PM EST
C$1.75
-C$0.04(-1.22%)
Day’s Range― - ―
52-Week RangeC$1.55 - C$3.10
Previous CloseN/A
Volume11.70K
Average Volume (3M)17.17K
Market Cap
C$59.38M
Enterprise ValueC$45.14M
Total Cash (Recent Filing)C$16.57M
Total Debt (Recent Filing)C$1.77M
Price to Earnings (P/E)35.3
Beta0.31
Next Earnings
Aug 31, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding27,618,076
10 Day Avg. Volume12,083
30 Day Avg. Volume17,167
Financial Highlights & Ratios
PEG Ratio-0.88
Price to Book (P/B)1.87
Price to Sales (P/S)1.75
P/FCF Ratio34.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$2.90Price Target Upside65.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.07
Revenue Forecast (FY)C$36.36M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage (debt-to-equity ~0.08 TTM) and a sizable equity base provide durable financial flexibility. This reduces refinancing and solvency risk, supports R&D and manufacturing investments, and preserves optionality to pursue partnerships or absorb demand shocks over the next several quarters.
Positive Cash GenerationSustained positive operating cash flow (~$6.1M) and free cash flow (~$4.7M) underpin internal funding capacity for working capital, capex, and commercialization. Reliable cash conversion supports steady operations and reduces dependence on external financing across a multi-quarter horizon.
Return To ProfitabilityThe business has moved from prior loss years to profitable operations with ROE ~3% TTM, indicating structural recovery. Restored profitability signals product-market fit and improved cost coverage, making profit sustainability and incremental margin expansion realistic over the medium term.
Bears Say
Margin CompressionA marked gross margin decline from ~61% to ~52% TTM is a durable headwind to profitability. Unless cost structure or pricing is addressed, lower gross margins constrain operating leverage, reduce free cash flow potential, and make consistent margin recovery difficult over several quarters.
Top-line WeaknessNegative revenue growth (≈-3.4% recent) signals soft demand or mix pressures that can persist if adoption or distribution doesn't expand. Weak or shrinking sales undermine scale benefits, hamper margin recovery, and limit the firm's ability to invest in commercialization and R&D sustainably.
Declining FCF GrowthAlthough FCF is positive, the meaningful decline versus the prior period highlights weakening conversion or higher cash intensity. Continued negative FCF growth could stress reinvestment, slow deleveraging or partnerships, and reduce the buffer to absorb future operational setbacks.
Covalon Technologies News
COV FAQ
What was Covalon Technologies Ltd’s price range in the past 12 months?
Covalon Technologies Ltd lowest stock price was C$1.55 and its highest was C$3.10 in the past 12 months.
What is Covalon Technologies Ltd’s market cap?
Covalon Technologies Ltd’s market cap is C$59.38M.
When is Covalon Technologies Ltd’s upcoming earnings report date?
Covalon Technologies Ltd’s upcoming earnings report date is Aug 31, 2026 which is in 86 days.
How were Covalon Technologies Ltd’s earnings last quarter?
Covalon Technologies Ltd released its earnings results on May 21, 2026. The company reported C$0.04 earnings per share for the quarter, beating the consensus estimate of C$0.02 by C$0.02.
Is Covalon Technologies Ltd overvalued?
According to Wall Street analysts Covalon Technologies Ltd’s price is currently Undervalued.
Does Covalon Technologies Ltd pay dividends?
Covalon Technologies Ltd pays a Notavailable dividend of C$0.15 which represents an annual dividend yield of N/A. See more information on Covalon Technologies Ltd dividends here
What is Covalon Technologies Ltd’s EPS estimate?
Covalon Technologies Ltd’s EPS estimate is 0.02.
How many shares outstanding does Covalon Technologies Ltd have?
Covalon Technologies Ltd has 27,618,076 shares outstanding.
What happened to Covalon Technologies Ltd’s price movement after its last earnings report?
Covalon Technologies Ltd reported an EPS of C$0.04 in its last earnings report, beating expectations of C$0.02. Following the earnings report the stock price went down -3.846%.
Which hedge fund is a major shareholder of Covalon Technologies Ltd?
Currently, no hedge funds are holding shares in TSE:COV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Covalon Technologies Ltd
Covalon Technologies Ltd. researches, develops, manufactures, commercializes, and licenses medical technologies and products in the United States, Canada, Europe, the Middle East, Asia, Latin America, and internationally. The company has 3 proprietary platform technologies, including collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; antimicrobial silicone adhesive platform that is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity; and medical coating platform, a proprietary process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. Its products include wound care dressings; surgical and peri-operative products; and infection management products. The company offers its products under the Covalon brand name through third-party distribution networks and company's direct sales force. It serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. The company is headquartered in Mississauga, Canada.
COV Stock 12 Month Forecast
Average Price Target
C$2.90
▲(65.71% Upside)
Technical Analysis
Medicenna Therapeutics Corp
―
Medmira
―
Sernova
―
NurExone Biologic
―
Defence Therapeutics
―